# US 12,110,294 B2 · CD73 compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,110,294 B2
- Document ID: US12110294B2
- Status: Granted
- Kind: B2
- Application number: 17/243,911
- Filed: 2021-04-29
- Published: 2023-02-09
- Granted: 2024-10-08
- Earliest claimed: 2020-05-01
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Mark J. Bartlett; Gregory F. Chin; Michael O. Clarke; Jennifer L. Cosman; Deeba Ensan; Bindu Goyal; Stephen Ho; Hon C. Hui; Richard L. Mackman; Michael R. Mish; Scott D. Schroeder; Nathan D. Shapiro; Dustin S. Siegel; Doris T. Tang; Hai Yang
- Web page: https://patentgrep.com/patent/US12110294B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.

## Claims

### Claim 1

A compound selected from the group consisting of:

### Claim 2 (depends on 1)

The compound of claim 1, which is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, further comprising one or more additional therapeutic agents.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the additional therapeutic agent is independently an anti-neoplastic agent, chemotherapy, radiation therapy, or resection therapy.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the additional therapeutic agent is independently rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, nivolumab, atezolizumab or ipilimumab.

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5, wherein the additional therapeutic agent is a PD-1 or PD-L1 inhibitor.